Multiple sclerosis patients and COVID-19

Mado, Hubert; Adamczyk-Sowa, Monika

doi:10.1186/s41983-021-00287-3

Cited by 7 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SARS‐CoV‐2 infection is not caused by MS by itself. Nevertheless, there is a dearth of knowledge about SARS‐CoV‐2 infection's effects on MS 44 . T lymphocytes contribute significantly to antiviral immunity.…”

Section: Discussionmentioning

confidence: 99%

The association between various viral infections and multiple sclerosis: An umbrella review on systematic review and meta‐analysis

Bakhshi,

Eslami,

Norouzi

et al. 2023

Reviews in Medical Virology

View full text Add to dashboard Cite

Multiple Sclerosis (MS) is one of the immune‐mediated demyelinating disorders. Multiple components, including the environment and genetics, are possible factors in the pathogenesis of MS. Also, it can be said that infections are a key component of the host's response to MS development. Finally, we evaluated the relationship between different pathogens and MS disease in this umbrella research. We systematically collected and analysed multiple meta‐analyses focused on one particular topic. We utilised the Scopus, PubMed, and Web of Science databases starting with inception until 30 May 2023. The methodological quality of the analysed meta‐analysis has been determined based on Assessing the Methodological Quality of Systematic Reviews 2 and Grade, and graph construction and statistical analysis were conducted using Comprehensive Meta‐Analysis. The Confidence Interval of effect size was 95% in meta‐analyses, and p < 0.05 indicated a statistically meaningful relationship. The included studies evaluated the association between MS and 12 viruses containing SARS‐CoV‐2, Epstein–Barr virus (EBV), Hepatitis B virus, varicella–zoster virus (VZV), human herpesvirus 6 (HHV‐6), HHV‐7, HHV‐8, HSV‐1, HSV‐2, Cytomegalovirus, Human Papillomavirus, and influenza. SARS‐CoV‐2, with a 3.74 odds ratio, has a significantly more potent negative effect on MS among viral infections. After that, EBV, HHV‐6, HSV‐2, and VZV, respectively, with 3.33, 2.81, 1.76, and 1.72 odds ratios, had a significantly negative relationship with MS (p < 0.05). Although the theoretical evidence mostly indicates that EBV has the greatest effect on MS, recent epidemiological studies have challenged this conclusion and put forward possibilities that SARS‐CoV‐2 is the culprit. Hence, it was necessary to investigate the effects of SARS‐CoV‐2 and EBV on MS.

show abstract

Section: Discussionmentioning

confidence: 99%

The association between various viral infections and multiple sclerosis: An umbrella review on systematic review and meta‐analysis

Bakhshi,

Eslami,

Norouzi

et al. 2023

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…Cladribine and alemtuzumab as B-cell depletion agents may enhance the risk of susceptibility to COVID-19 infection; thus their regular application or initiation of treatment should be considered carefully [49,[53][54][55]58]. Alemtuzumab causes severe lymphopenia via decreasing the count of T-and B-cells for several months, thus increasing the incidence of infection following administration.…”

Section: Dmts and Covid-19 Disease: Benefits-to-risk Ratiomentioning

confidence: 99%

Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination

Golshani

Hrdý

2022

Vaccines

View full text Add to dashboard Cite

This article reviews the literature on SARS-CoV-2 pandemic and multiple sclerosis (MS). The first part of the paper focuses on the current data on immunopathology of SARS-CoV-2 and leading vaccines produced against COVID-19 infection. In the second part of the article, we discuss the effect of Disease Modifying Therapies (DMTs) on COVID-19 infection severity or SARS-CoV-2 vaccination in MS patients plus safety profile of different vaccine platforms in MS patients.

show abstract

“…PwMS, especially those with severe forms of the disease, are generally more prone to infections [ 16 , 20 ]. The pandemic has also had a negative impact on the mental health of pwMS [ 21 ], since the fear of get the disease [ 22 ], home confinement [ 23 ], and social distancing have caused an increase in levels of anxiety and depression in these patients [ 21 ].…”

Section: Interaction Covid-19 and Multiple Sclerosismentioning

confidence: 99%

“…Due to the higher rate of infection and mortality because of the COVID-19, among patients with chronic diseases, a concern has been raised with pwMS, since, normally, their treatment is based on DMTs [ 16 ]. In general, 70% of pwMS are treated with DMTs [ 31 , 32 ].…”

Section: Interaction Covid-19 and Multiple Sclerosismentioning

confidence: 99%

“…SARS-CoV-2 has become a serious challenge for many areas of medicine, including neurology [ 15 ]. In this sense, since the beginning of the pandemic, there has been a special concern for those people suffering from Multiple Sclerosis (MS), especially those who are being treated with disease-modifying therapies (DMTs) [ 16 ], since it is believed that these patients may be at higher risk of infection or of having a more severe course of COVID-19 than the general population. This disease affects 2.5 million people in the world [ 17 ], being the most common cause of non-traumatic disability in young adults [ 18 ] between 20 and 30 years of age [ 19 ] (Fig.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19

et al. 2022

View full text Add to dashboard Cite

The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis, as these people are believed to be at increased risk of infection, especially those being treated with disease-modifying therapies. Therefore, the objective of this review was to describe how COVID-19 affects people who suffer from Multiple Sclerosis, evaluating the risk they have of suffering an infection by this virus, according to the therapy to which they are subjected as well as the immune response of these patients both to infection and vaccines and the neurological consequences that the virus can have in the long term. The results regarding the increased risk of infection due to treatment are contradictory. B-cell depletion therapies may cause patients to have a lower probability of generating a detectable neutralizing antibody titer. However, more studies are needed to help understand how this virus works, paying special attention to long COVID and the neurological symptoms that it causes.

show abstract

Multiple sclerosis patients and COVID-19

Cited by 7 publications

References 9 publications

The association between various viral infections and multiple sclerosis: An umbrella review on systematic review and meta‐analysis

The association between various viral infections and multiple sclerosis: An umbrella review on systematic review and meta‐analysis

Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination

SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19

Contact Info

Product

Resources

About